Angiotensin-converting enzyme activity in hypertensive subjects after magnesium sulfate therapy.
Angiotensin-converting enzyme is a peptidase involved in the formation of angiotensin II and the inactivation of bradykinin. In a previous study we found elevated angiotensin-converting enzyme activity in women with pregnancy-induced hypertension prior to magnesium sulfate therapy and lower levels during therapy. This prospective study was undertaken in order to determine if angiotensin-converting enzyme activity indeed decreased after magnesium sulfate therapy. Sixteen patients with pregnancy-induced hypertension were studied before and during magnesium sulfate therapy. Angiotensin-converting enzyme activity was found to decrease 1 to 8 hours into therapy and then plateau between 9 and 24 hours. Possible mechanisms for this observation are discussed.
D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D007703:Peptidyl-Dipeptidase A / Q000097:blood*; D011225:Pre-Eclampsia / Q000201:enzymology; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy / Q000201:enzymology*; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies
D008278:Magnesium Sulfate; D007703:Peptidyl-Dipeptidase A